Navigation Links
MED3OOO Appoints Angela Hoffman as Chief Compliance Officer
Date:10/7/2008

s. Hoffman earned a BSN and MSN with a concentration in Health Care Management from La Roche College in Pittsburgh, PA.

Photo of Angela Hoffman: http://www.ereleases.com/pr/2008-MED3OOO.jpg

About MED3OOO

(Logo: http://www.ereleases.com/pr/MED3OOO_logo.jpg )

MED3OOO, a leader in healthcare management services, information management, and technologies, advances the quality and performance of healthcare delivery for providers and payors across the United States. Focused on the provision of evidence-based management and population health management, MED3OOO empowers over 15,000 physician, hospital, employer, health system, and municipal clients across the United States. For more information, please visit http://www.MED3000.com or contact Karla Sartori, MED3OOO Corporate Marketing, at 412-937-8887 or Karla_Sartori@MED3000.com.

CONTACT:

Karla Sartori

412-937-8887 ext. 325

Karla_Sartori@MED3000.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE MED3OOO, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. MED3OOO Client Wins IHA Pay-for-Performance Award
2. Molina Medical Group Selects MED3OOO
3. PSA, LLC, a MED3OOO Company, Selected as a Member of the SC Provider Outreach and Education Advisory Group
4. MED3OOO and Mitsui & Co. Complete U.S. and Global Healthcare Partnership Agreement
5. WorldHeart Appoints David Pellone Chief Financial Officer
6. Novo Nordisk Appoints New Leader of North American Business
7. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
8. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
9. Resonant Medical Appoints New Vice President of Global Sales
10. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
11. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2009)... in military families may suffer from more emotional and ... older children and girls struggling the most when a ... Corporation study. , Researchers found that having a parent ... a non-deployed parent who has struggled with emotional problems ... struggle themselves, according to the study published online by ...
(Date:12/6/2009)... NEW ORLEANS and SUNNYVALE, Calif., Dec. 6 /PRNewswire-FirstCall/ ... announced interim results from a Phase I/II study ... relapsed / recurrent non-Hodgkin,s Lymphoma (NHL) treated with ... The data were presented today at the 51st ... LA (Abstract # 2726). ,, PCI-24781 is ...
(Date:12/6/2009)... growth factor, researchers say , , SUNDAY, Dec. 6 ... from the main tumor to other parts of the ... TGFb, which may prove a promising target for new ... , Previous studies have shown that TGFb (transforming growth ... this new study, a team from Cancer Research UK ...
(Date:12/6/2009)... Sickle cell disease, a condition characterized by deformed ... the most common genetic blood disorders affecting millions ... 70,000 Americans.(1) Research presented today at the 51st ... highlights intriguing studies on the acute danger that ... blood disorder, evaluations of both new and standard ...
(Date:12/6/2009)... the Greater VA Healthcare System in West Los Angeles, will once ... soar to more than 5,000 veterans, active military personnel and their ... ... -- Volunteer organizations and members of the community, in cooperation with ... again create a holiday party. This year,s attendance is expected to ...
Breaking Medicine News(10 mins):Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 2Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 2Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 4Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 5Health News:Breast Cancer's Spread Now Better Understood 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 3Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 4Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 6Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 7Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 8Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 9Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3
... diastolic blood pressure under 70 mm Hg coupled with ... risk of heart attack and stroke than indicated by ... UC Irvine study. , Dr. Stanley Franklin and colleagues ... conjunction with researchers at the Framingham Heart Study reviewed ...
... Cogdell Spencer Inc. (NYSE: CSA ) announces ... South Central Region for the Company,s wholly owned subsidiary, ... Dallas office, Mr. Dagar will focus on developing and ... design-build and development projects in the Region which includes ...
... , , WEDNESDAY, Feb. 18 (HealthDay News) -- A new report ... the United States and in far reaches of the globe, ... , The implications of this, according to Dr. Kevin A. ... on people who may not align with the types of ...
... --Obstetrician Developed Health & Beauty Products for Pregnant Women ... With Hollywood,s baby boom in full-swing, Beaute de ... beauty products designed exclusively for the pregnant woman by ... such celebrity moms-to-be including actresses Penelope Ann Miller, Salli ...
... Home Caregivers Urge Pursuit of Consistent, Logical Policy in ... Mo., Feb. 18 /PRNewswire-USNewswire/ -- A national ... Administration to build upon its success in the federal ... nursing care in the soon-to-be released fiscal 2010 budget ...
... more prevalent than full-blown stroke in people under 65, MRI ... strokes" rarely produce symptoms, but a new study suggests they ... strokes in people under 65 years of age, and not ... new study was conducted by a team at Boston University ...
Other Medicine News:Health News:Cogdell Spencer Announces Dagar as President of the South Central Region 2Health News:Cogdell Spencer Announces Dagar as President of the South Central Region 3Health News:Many Clinical Trials Moving Overseas 2Health News:Many Clinical Trials Moving Overseas 3Health News:Hollywood's Celebrity Moms-To-Be Get Acquainted With All-Natural Beaute de Maman Product Line 2Health News:Hollywood's Celebrity Moms-To-Be Get Acquainted With All-Natural Beaute de Maman Product Line 3Health News:Coalition to Protect Senior Care Urges Obama Administration to Support Frontline Caregivers by Protecting Medicare Funding in FY 2010 Budget Blueprint 2Health News:Silent Strokes More Common in Younger People Than Thought 2Health News:Silent Strokes More Common in Younger People Than Thought 3
(Date:12/4/2009)... SAN DIEGO, Calif., Dec. 4 Suneva Medical, a ... of Philip Ranker as Vice President and Chief Financial ... all Suneva Medical,s general and administrative functions including finance, ... will also serve on the Company,s senior management team. ...
(Date:12/4/2009)... Inc. (NYSE: WPI ), a leading global ... Laboratories, Inc.-Florida, filed an Abbreviated New Drug Application (ANDA) ... to market its 8mg ramelteon tablets prior to the ... Limited. Watson,s 8mg ramelteon tablet product is a ...
(Date:12/4/2009)... Dec. 4 Northwest Biotherapeutics, Inc. ("NWBT" or the ... US Patent and Trademark Office has allowed its patent ... stages of the manufacture of the Company,s DCVax® therapeutic ... to the very high concentration of dendritic cells (which ...
Breaking Medicine Technology:Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5Forest Laboratories Announces Positive Top line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community acquired Bacteria 49495 1Forest Laboratories Announces Positive Top line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community acquired Bacteria 49495 2Forest Laboratories Announces Positive Top line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community acquired Bacteria 49495 3Forest Laboratories Announces Positive Top line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community acquired Bacteria 49495 4Forest Laboratories Announces Positive Top line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community acquired Bacteria 49495 53 to 6 months to lose weight gained in pregnancy is normal 8926 13 to 6 months to lose weight gained in pregnancy is normal 8926 2Ken May Re Elected for Second Term as Chairman of the Board of March of Dimes 49490 1
1000 L, Bulk Recommended for 500 and 1000 L pipettes....
Inquire...
... have been designed to optimize the accuracy ... our tip products is widely recognized by ... has been extended over the years and ... and special tips including filter tips, certified ...
This 100 µL is the equivalent to the "Universal Blue" tips and fits virtually every manufacturer's 1000 µL Pipettor....
Medicine Products: